An observational study in Lupus Nephritis, Systemic Lupus Erythematosus and Kidney Diseases, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Assiut University · Observational
Among 22 studies in Lupus Nephritis by Assiut University — 17 open to participants now, 17 under way, none of them phase 3. Lupus Nephritis · Assiut University.
Among the 22 studies in Lupus Nephritis by Assiut University, this one is the 6th largest by planned enrollment of the 21 observational ones, is one of 8 that started in 2026, is one of 21 observational ones, reaches primary completion later than 11 of the 16 other live ones, and was the 20th registered.
340 studies on the registry are indexed under Lupus Nephritis; 135 are open to participants now.
This study's planned enrollment of 100 is close to the median of 100 across 77 observational studies indexed under Lupus Nephritis.
Browse Lupus Nephritis studies →17 of the 22 studies in Lupus Nephritis by Assiut University are open now, in 1 country. Each count lists the studies.
Of the 88 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 51 (58%) stop at 75 or younger; 29 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →22 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 8 started in 2026.
Median enrollment 60 across the 1 interventional studies, 96 across the 21 observational. None of them has completed or been terminated yet.
Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
7 of the studies in Lupus Nephritis by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06564181Assiut UniversityThe Relation Between Serum Zinc and Lupus Nephritis | 2026-12 |
| NCT07505576Assiut UniversityAnti-alpha-actinin Antibodies and Lupus Nephritis Activity | 2027-04-01 |
| NCT06837558Assiut UniversityPredictors of Bone Mineral Density in Lupus Nephritis Activity | 2027-04-01 |
| NCT07780045Assiut UniversitySII and SIRI as Prognostic Biomarkers in Lupus Nephritis | 2027-08-19 |
| NCT07837544Assiut UniversityDiastolic Dysfunction and Inflammatory Biomarkers in Lupus Nephritis | 2027-09-20 |
Among the 22 studies in Lupus Nephritis by Assiut University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This prospective observational study aims to evaluate the prognostic utility of the Systemic Immune-Inflammation Index (SII) and Systemic Inflammation Response Index (SIRI) as novel inflammatory biomarkers for monitoring disease activity and predicting renal progression, flares, and outcomes in patients with lupus nephritis.
Lupus nephritis (LN) is a common and serious manifestation of systemic lupus erythematosus (SLE) that can lead to progressive renal damage and end-stage renal disease. Current assessment of disease activity and prognosis relies mainly on proteinuria, serum creatinine, estimated glomerular filtration rate (eGFR), and kidney biopsy, which is invasive and not always feasible for repeated monitoring.
Simple blood count-derived inflammatory indices, such as the Systemic Immune-Inflammation Index (SII) and the Systemic Inflammation Response Index (SIRI), have recently emerged as potential biomarkers of systemic inflammation. These indices are inexpensive, readily available, and may reflect disease activity and renal risk in lupus nephritis. However, their prognostic value remains incompletely established, particularly in prospective settings.
This prospective observational study will evaluate the ability of SII and SIRI to monitor disease activity and predict renal flares and outcomes in patients with lupus nephritis over a 12-month follow-up period.
Adults with lupus nephritis attending the Internal Medicine Department (Nephrology and Rheumatology units) at Assiut University Hospitals who meet the study eligibility criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Correlation of SII and SIRI with disease activity
Correlation between Systemic Immune-Inflammation Index (SII) and Systemic Inflammation Response Index (SIRI) levels with disease activity assessed by SLEDAI-2K and Renal SLEDAI scores.
Time frame: Baseline, 6 months, and 12 months
Association of SII and SIRI with renal function parameters
Association between SII and SIRI levels and renal function parameters including serum creatinine, eGFR, and proteinuria.
Time frame: Baseline, 6 months, and 12 months
Predictive value of SII and SIRI for renal flares
Ability of baseline and follow-up SII and SIRI values to predict the occurrence of renal flares
Time frame: 12 months
Association of SII and SIRI with clinical outcomes
Relationship between SII and SIRI levels and short-term clinical outcomes including renal remission or disease progression.
Time frame: 12 months
No study locations are listed for this record.
Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.